IACT is a collaborative project, supported by the European Commission’s 7th framework programme 2012 and specifically addresses the call:
HEALTH-2012-INNOVATION-1-1.2-1: HEALTH.2013.2.4.1-2: Strengthening the cancer patient's immune system.
The aim of this call is to translate clinical observations concerning cancer immunotherapy into improving treatment efficacy of future immunotherapeutic strategies. This can include: (1) cell- or antibody-based immunotherapy; (2) therapeutic cancer vaccines directed against clinically relevant tumor and/or host antigens; (3) immune evasion impacting on clinically relevant tumor-host microenvironment interactions in localized or systemic disease. Appropriate tumor response criteria are to be implemented and existent or newly developed assays harmonized while validating cancer immunotherapeutic regimens in preclinical models or first-in-human trials. Involvement of industry, in particular SMEs, is strongly recommended.
IACT is supported with 6 Mio € by the EU. The total project has a volume of >8 Mio €. The project started in November 2013 and is planned to be completed in December 2018.